Feng Zhou
Zhejiang Chinese Medical University(CN)Westlake University(CN)Simcere Pharmaceutical (China)(CN)Acceleron Pharma (United States)(US)Shanghai Pesticide Research Institute(CN)Hangzhou First People's Hospital(CN)Henan Institute of Science and Technology(CN)Incyte (United States)(US)
Publications by Year
Research Areas
Multiple Myeloma Research and Treatments, Myeloproliferative Neoplasms: Diagnosis and Treatment, Prenatal Substance Exposure Effects, Epigenetics and DNA Methylation, Liver physiology and pathology
Most-Cited Works
- → Discovery of (S)-1-(1-(Imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine (Volitinib) as a Highly Potent and Selective Mesenchymal–Epithelial Transition Factor (c-Met) Inhibitor in Clinical Development for Treatment of Cancer(2014)133 cited
- → Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer(2011)121 cited
- → Chromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate cancer(2020)120 cited
- → Volitinib, a potent and highly selective c‐Met inhibitor, effectively blocks c‐Met signaling and growth in c‐MET amplified gastric cancer patient‐derived tumor xenograft models(2014)119 cited
- → FGF/FGFR signaling: From lung development to respiratory diseases(2021)106 cited